Is It Too Late to Buy Moderna After Its 40% Gain?
Moderna (NASDAQ: MRNA) offered investors a big buying opportunity over the past six weeks. Shares of the coronavirus vaccine maker dropped as much as 36% from their all-time high. At the same time, news has been positive. The company continued the rollout of its vaccine and announced enrollment in trials of booster candidates targeting variants of concern.
Then, finally, the rebound Moderna investors were waiting for gradually happened. Over the past three weeks, the stock has climbed about 40%. In fact, today the shares are only a few dollars away from Wall Street's average 12-month price estimate.
Now, the question: Is it too late to buy Moderna shares? Let's find out.
Source Fool.com
